This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Unryn, B. M. Articles by Riabowol, K. T. Search for Related Content PubMed PubMed Citation Articles by Unryn, B. M. Articles by Riabowol, K. T.

Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer

Authors' Affiliations: ¹ Departments of Biochemistry and Molecular Biology and Oncology, The University of Calgary Health Sciences Centre; ² Tom Baker Cancer Centre and University of Calgary, Calgary, Alberta, Canada; and ³ Division of Hematology/Oncology, Miller School of Medicine, University of Miami and U.M. Sylvester Comprehensive Cancer Centre, Braman Family Breast Cancer Institute, Miami, Florida

Requests for reprints: Karl T. Riabowol, Departments of Biochemistry and Molecular Biology and Oncology, The University of Calgary Health Sciences Centre, No. 370, Heritage Medical Research Building, 3330 Hospital Drive Northwest, Calgary, Alberta T2N 4N1, Canada. Phone: 403-220-8695; Fax: 403-270-0834; E-mail: karl{at}ucalgary.ca.

Purpose: Chronic viral infection and combinations of chemotherapeutic drugs have been reported to accelerate telomere erosion. Here, we asked if chemoradiotherapy, using the single agent cisplatin, would accelerate telomere loss in head and neck cancer patients, and whether loss was linked to smoking status, age, gender, or stage of disease at diagnosis.

Experimental Design: Blood samples were collected from 20 patients with squamous cell cancer of the head and neck before, during, and after chemoradiotherapy. Following DNA isolation from peripheral blood mononuclear cells, telomere length was measured by terminal restriction fragment analysis.

Results: Chemoradiotherapy increased the rate of telomere erosion >100-fold. Telomere length before treatment in chemoradiotherapy patients was similar to age-matched controls. Although smokers began with significantly shorter telomeres, smoking status did not affect chemoradiotherapy-induced attrition, nor did gender or stage of disease. We also make the novel observation that a significantly greater telomere loss occurred in response to treatment in older patients, with those younger than 55 years losing an average of 400 bp of telomeric DNA compared with the 880 bp lost by those over 55 years.

Conclusions: The lack of telomere length difference before treatment suggests that shortened telomeres may not be a risk factor for development of head and neck cancer in the age range we examined. Chemoradiotherapy caused a severe telomere length reduction in all patients. The significant difference seen in the elderly (P = 0.018) suggests that chemoradiotherapy may have more severe effects on the replicative capacity of blood cells in older patients.

This article has been cited by other articles:

				S. Chakraborty, C.-L. Sun, L. Francisco, M. Sabado, L. Li, K. L. Chang, S. Forman, S. Bhatia, and R. Bhatia Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma J. Clin. Oncol., February 10, 2009; 27(5): 791 - 798. [Abstract] [Full Text] [PDF]

				J. Shen, M. B. Terry, I. Gurvich, Y. Liao, R. T. Senie, and R. M. Santella Short Telomere Length and Breast Cancer Risk: A Study in Sister Sets Cancer Res., June 1, 2007; 67(11): 5538 - 5544. [Abstract] [Full Text] [PDF]